Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

PURPOSE: PROSTVAC, a viral vector–based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further investigated those findings. PATIENTS AND METHODS: Patients were randomly as...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Gulley, James L., Borre, Michael, Vogelzang, Nicholas J., Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C., Pook, David W., Rathenborg, Per, Flaig, Thomas W., Carles, Joan, Saad, Fred, Shore, Neal D., Chen, Liddy, Heery, Christopher R., Gerritsen, Winald R., Priou, Frank, Langkilde, Niels C., Novikov, Andrey, Kantoff, Philip W.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2019
Pynciau:
RAPID COMMUNICATION
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494360/
https://ncbi.nlm.nih.gov/pubmed/30817251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02031
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg